CDR-Life Presents Precise Tumor and Patient Selection for CDR404: First-of-its-Kind Dual MAGE-A4 T-cell Engager, at ESMO Congress 2023

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec

Related Keywords

Spain ,Madrid ,Switzerland ,United States ,Emiliano Calvo ,Swethajit Biswas ,Globe Newswire Inc ,Cancer Genome Atlas ,Senior Investigator ,Chief Medical Officer ,Presentation Details ,Precise Tumor ,Patient Selection ,Squamous Cell Carcinoma ,Lung Adenocarcinoma ,Bladder Cancer ,Rna Expression ,Solid Tumors ,Bladder Cancers ,Expression Levels ,Phase 1 Trial ,Tumor Types ,